IP Library › Granted Patent US 12,350,328
Granted Patent B2
US 12,350,328 · App. 17/434,489 · Granted Jul 8, 2025

Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses

Inventors: Luis Martinez-Sobrido (Rochester, NY); Thomas Chambers (Lexington, KY); Kendall Wayne King (Kalamazoo, MI)
Assignees: University of Rochester; UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION; ZOETIS SERVICES LLC
A61K39/145A61P31/16A61K2039/5254A61K2039/552A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,350,328
App. No.
17/434,489
Granted
Jul 8, 2025
Kind
B2
Abstract

The present invention provides compositions and methods related to equine live-attenuated influenza vaccines. In one aspect, the invention relates to a composition comprising a multivalent equine live-attenuated influenza vaccine comprising a first live-attenuated influenza virus expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and a second live-attenuated influenza virus expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second live-attenuated influenza virus expresses HA, NA, or a combination thereof of A/equine/Lancashire/1/2016 H3N8.

Claims (25)

1. A multivalent immunological composition comprising two or more equine live-attenuated influenza viruses (LAIV), comprising:

a first LAIV expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and

a second LAIV expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second LAIV expresses hemagglutinin (HA), Neuraminidase (NA), or a combination thereof of A/equine/Lancashire/1/2016 H3N8,

wherein each LAIV comprises one or more mutations in one or more of: segment 1 and segment 2 of the viral genome,

wherein segment 1 of the viral genome encodes a polymerase basic 2 (PB2) protein and segment 2 of the viral genome encodes a polymerase basic 1 (PB1) protein.

2. The composition of claim 1 , wherein the first LAIV expresses HA, NA, or a combination thereof of A/equine/Ohio/1/2003 H3N8.

3. The composition of claim 1 , wherein the first LAIV expresses HA, NA, or a combination thereof of A/equine/Texas/6/2017 H3N8.

4. The composition of claim 1 , wherein segment 1 of the first LAIV and/or the second LAIV comprises the nucleic acid sequence set forth in SEQ ID NO: 1.

5. The composition of claim 1 , wherein segment 2 of the first LAIV and/or the second LAIV comprises the nucleic acid sequence set forth in SEQ ID NO: 3.

6. The composition of claim 1 , wherein at least one LAIV comprises one or more mutations in segment 1, which encodes a mutant PB2.

7. The composition of claim 6 , wherein the mutant PB2 comprises a N265S point mutation relative to SEQ ID NO: 6.

8. The composition of claim 7 , wherein the mutant PB2 comprises the amino acid sequence set forth in SEQ ID NO: 2.

9. The composition of claim 1 , wherein at least one LAIV comprises one or more mutations in segment 2, which encodes a mutant PB1.

10. The composition of claim 9 , wherein the mutant PB1 comprises one or more of: a K391E point mutation relative to SEQ ID NO: 8, an E581G point mutation relative to SEQ ID NO: 8, and/or an A661T point mutation relative to SEQ ID NO: 8.

11. The composition of claim 10 , wherein the mutant PB1 comprises a K391E point mutation relative to SEQ ID NO: 8, an E581G point mutation relative to SEQ ID NO: 8, and an A661T point mutation relative to SEQ ID NO: 8.

12. The composition of claim 11 , wherein the mutant PB1 comprises the amino acid sequence set forth in SEQ ID NO: 4.

13. The composition of claim 1 , wherein each LAIV comprises one or more mutations in segment 1, which encodes a mutant PB2; and one or more mutations in segment 2, which encodes a mutant PB1.

14. The composition of claim 13 , wherein the mutant PB2 comprises a N265S point mutation relative to SEQ ID NO: 6 and wherein the mutant PB1 comprises a K391E point mutation relative to SEQ ID NO: 8, an E581G point mutation relative to SEQ ID NO: 8, and an A661T point mutation relative to SEQ ID NO: 8.

15. The composition of claim 1 , wherein the composition is used for the treatment of equine influenza in a subject.

16. The composition of claim 1 , wherein segment 1 of each LAIV is derived from segment 1 of A/equine/Ohio/1/2003; and wherein segment 2 of each LAIV is derived from segment 2 of A/equine/Ohio/1/2003.

17. A method for inducing an immune response against a plurality of equine influenza viruses in a subject, the method comprising administering to the subject the immunological composition of claim 1 .

18. The method of claim 17 , wherein the subject does not have equine influenza, and wherein the method induces immunity against equine influenza.

19. The method of claim 17 , wherein the subject is infected with equine influenza, and wherein the method induces a therapeutic immune response.

20. The method of claim 17 , wherein the immunological composition is administered intranasally, intratracheally, orally, intradermally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

21. The method of claim 17 , wherein the subject is a horse.

Continuity (2)
Provisional Application 62811112 · Feb 27, 2019
Related Publication 20220133877A1 · May 5, 2022
References Cited (56)
US 8137676B2 · Palese · 2012 [cited by examiner]
US 11576963B2 · Martinez-Sobrido · 2023 [cited by examiner]
US 11672852B2 · Verhoeven · 2023 [cited by examiner]
US 20160250318A1 · Eichmeyer · 2016 [cited by examiner]
US 20230372466A1 · Verhoeven · 2023 [cited by examiner]
ES 2393406T3 · 2012 [cited by examiner]
WO WO2011044561A9 · 2012 [cited by examiner]
WO WO2013030176A2 · 2013 [cited by examiner]
WO WO2015010073A1 · 2015 [cited by examiner]
WO WO2017210528A1 · 2017 [cited by examiner]
Crawford et al. 2012. ES 2393406 T3. Machine Translation. (Year: 2012). [cited by examiner]
Anonymous, “Equine influenza: OIE—World Organisation for Animal Health”, (Mar. 28, 2018), URL: http://www.oie.int/en/scientific-expertise/specific-information-and-recommendations/equine-influenza/, (Apr. 30, 2019), XP05… [cited by applicant]
Baker et al., 2013, “Protection against lethal influenza with a viral mimic.” J Virol, 87: 8591-8605. [cited by applicant]
Bin Zhou et al., “Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses”, Vaccine, Elsevier Ltd, GB, 30(24): 3691-3702. [cited by applicant]
Blanco-Lobo et al., 2019, “A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus.” Viruses. 11(10):933. [cited by applicant]
Blanco-Lobo et al., 2019, “Novel Approaches for The Development of Live Attenuated Influenza Vaccines.” Viruses, 11 (2):190. [cited by applicant]
Chambers and Reedy, 2014, “Equine influenza serological methods,” Methods Mol.Biol. 1161, 411-422. [cited by applicant]
Chambers et al., 2001, “A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge,” Equine Vet. J. 33, 630-636. [cited by applicant]
Chambers et al., 2009, “Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses,” Equine Vet. J. 41, 87-92. [cited by applicant]
Cheng et al., 2013, The Journal of infectious diseases, 208: 594-602. [cited by applicant]
Cox et al., 1988, “Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2).” Virology, 167: 554-567. [cited by applicant]
Cullinane A, Elton D, Mumford J. Equine influenza—surveillance and control. Influenza Other Respir Viruses. Nov. 2010;4(6):339-44. [cited by applicant]
Daly JM, Yates RJ, Browse G, Swann Z, Newton JR, Jessett D, Davis-Poynter N, Mumford JA. Comparison of hamster and pony challenge models for evaluation of effect of antigenic drift on cross protection afforded by equine… [cited by applicant]
Daly, Janet M., et al. “Equine influenza: a review of an unpredictable virus.” The Veterinary Journal 189.1 (2011): 7-14. [cited by applicant]
De Villiers et al., 2009, “Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.” Vaccine, 28: 228-234. [cited by applicant]
Emperador et al., 2016, “Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh.” Clin Infect Dis, 62(2):150-156. [cited by applicant]
Garner MG, Cowled B, East IJ, Moloney BJ, Kung NY. Evaluating the effectiveness of early vaccination in the control and eradication of equine influenza—a modelling approach. Prev Vet Med. Apr. 1, 2011;99(1):15-27. [cited by applicant]
Guo et al., 2014, “Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.” J Viral, 88: 12006-12016. [cited by applicant]
Jin et al., 2004, “Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60.… [cited by applicant]
Katsura et al., 2012, “A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine.” Vaccine, 30: 6027-6033. [cited by applicant]
Kohlmeier et al., 2009, “Immunity to respiratory viruses.” Annual review of immunology, 27: 61-82. [cited by applicant]
Lu et al., 2009, “Development and Evaluation of One-Step TaqMan Real-Time Reverse Transcription-PCR Assays Targeting Nucleoprotein, Matrix, and Hemagglutinin Genes of Equine Influenza Virus,” J. Clin. Microbiol. 47, 390… [cited by applicant]
Lunn et al., 2001, “Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression,” J. Am. Vet. Med. Assoc. 218, 900-906. [cited by applicant]
Mariana Baz et al., 2014, “A live attenuated H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.” Journal of Virology, 89(3): 1652-1659. [cited by applicant]
Martínez-Sobrido et al., 2010, “Generation of Recombinant Influenza Virus from Plasmid DNA.” J. Vis. Exp. (42), e2057. [cited by applicant]
Mumford et al., 1990, “Experimental infection of ponies with equine influenza (H3N8) viruses by intranasal inoculation or exposure to aerosols,” Equine Vet. J. 22, 93-98. [cited by applicant]
Murphy et al., 2002, “Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.” Viral immunology, 15: 295-323. [cited by applicant]
Nogales et al., 2014, “Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development.” J Virol, 88: 10525-10540. [cited by applicant]
Nogales et al., 2016, “Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.” J Virol, 90: 6291-6302. [cited by applicant]
Nogales et al., 2017, “Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines,” Virology, 500, 1-10. [cited by applicant]
Paillot R, El-Hage CM. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary. Pathogens. Jun. 10, 2016;5(2):42. [cited by applicant]
Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel). Nov. 14, 2014;2(4):797-831. [cited by applicant]
Powell et al., 2012, “Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity.” J Virol, 86: 13397-13406. [cited by applicant]
Rash et al., 2017, “Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015”, Pathogens, 6(1):6. [cited by applicant]
Rodriguez et al., “Development of a novel equine influenza virus live-attenuated vaccine,” 2018, Virology, vol. 516, pp. 76-85. [cited by applicant]
Rodriguez et al., 2017, “A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.” Vaccine. 35(34):4374-4381. [cited by applicant]
Rodriguez et al., 2017, “Influenza A Virus Studies in a Mouse Model of Infection,” J. Vis. Exp, 127, e55898. [cited by applicant]
Rodriguez, Laura, et al. “A live-attenuated influenza vaccine for H3N2 canine influenza virus.” Virology 504 (2017): 96-106. [cited by applicant]
Snyder et al., 1988, “Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.” J Viral, 62: 488-495. [cited by applicant]
Suguitan et al., 2006, “Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets,” PLoS Med. 3, e360. [cited by applicant]
Timoney, Peter J. “Factors influencing the international spread of equine diseases.” Veterinary Clinics of North America: Equine Practice 16.3 (2000): 537-551. [cited by applicant]
Townsend et al., 2001, “Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials,” Equine Vet. J. 33, 637-643. [cited by applicant]
Uraki et al., 2013, “A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.” J Viral, 87: 7874-7881. [cited by applicant]
Victor et al., 2012, “A replication-incompetent PB2-knockout influenza A virus vaccine vector.” J Viral, 86(8): 4123-4128. [cited by applicant]
Wilson and Robinson, 2000, “Field Safety of a Modified-Live, Cold-Adapted Intranasal Equine Influenza Vaccine (Heska TM Flu Avert TM I.N. Vaccine) in Horses,” J. Equine Vet. Sci. 20, 8-10. [cited by applicant]
Youngner et al., 2001, “Derivation and characterization of a live attenuated equine influenza vaccine virus,” Am. J. Vet. Res. 62, 1290-1294. [cited by applicant]